Latest Content

Pathos AI secured a $125 million upfront license to Alphamab's JSKN016 and a co-exclusive agreement with AstraZeneca to advance AZD4241, while Curium announced a deal to acquire Lantheus for up to $8 billion.

Incubate’s executive director discusses China’s rise in biotech and why the US’ best response may be to focus on its own issues.

AstraZeneca and BMS held merger talks, Incubate's John Stanford on fixing the US pharma ecosystem, and why real-time clinical trial data matters.

As multispecific antibodies and antibody drug conjugates outgrow legacy LIMS and ELN platforms, drug developers face a problem more costly than fragmented workflows: scientific reasoning evaporates at every handoff, forcing the next team to start from scratch.

The Swiss generic drugmaker says the agreement carries no admission of wrongdoing and will not affect its 2026 guidance or mid-term outlook.

A potential combination would create the world's largest pharmaceutical company by revenue.

Incubate’s executive director discusses China’s rise in biotech and why the US’ best response may be to focus on its own issues.

Clinical trials now generate 5.9 million datapoints per Phase III protocol — and most sponsors are still managing them manually.

In today's Pharmaceutical Executive Daily, FDA's advisory committee votes in favor of Replimune's RP1 efficacy data in advanced melanoma, three clinical-stage biopharmaceutical companies file for IPOs spanning cardiovascular, immune, and metabolic disease, and a new analysis examines why two-thirds of pharmaceutical product launches fail to meet expectations.

Braveheart Bio, Attovia, and Vogenx have all announced Initial public offerings, focusing on a cardiovascular drug, an immune-disease biologics platform, and a metabolic disease program.

John Stanford, executive director at Incubate, explains the COINS Act debate: should Treasury restrict US biotech investment in China, and what happens to American leadership if it does.

In today's Pharmaceutical Executive Daily, Johnson & Johnson, Processa Pharmaceuticals, and Relation strike new deals spanning cell therapy, BTK inhibition, and AI-driven target discovery, Inizio Engage launches Connected Insights to turn medical information interactions into strategic intelligence, and a commentary argues pharma companies need to manage direct-to-patient sales as a core commercial channel rather than a side program.

Inizio Engage is expanding its Global Medical Information platform with Connected Insights to convert the more than one million scientific interactions its teams handle annually into actionable intelligence.